Sarepta Therapeutics Inc's Comment on Supply Chain
The company has a supply agreement with Catalent for the manufacture and supply of ELEVIDYS, effective until December 31, 2028, subject to earlier termination under specified conditions. The company is contractually obligated to pay for certain manufacturing batches, including deferred payments due in 2026 and 2027. Additionally, the company holds an exclusive license agreement with Nationwide Children’s Hospital for the development, manufacture, and commercialization of ELEVIDYS worldwide. This agreement includes milestone payments, royalties on net sales, and sublicensing remuneration. Both agreements contain termination provisions related to material breaches and other specified circumstances.
Sarepta Therapeutics Inc's Comment on Supply Chain
The company has a supply agreement with Catalent for the manufacture and supply of ELEVIDYS, effective until December 31, 2028, subject to earlier termination under specified conditions. The company is contractually obligated to pay for certain manufacturing batches, including deferred payments due in 2026 and 2027. Additionally, the company holds an exclusive license agreement with Nationwide Children’s Hospital for the development, manufacture, and commercialization of ELEVIDYS worldwide. This agreement includes milestone payments, royalties on net sales, and sublicensing remuneration. Both agreements contain termination provisions related to material breaches and other specified circumstances.
Sources:
Sarepta Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Sarepta Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
